Biopsy-proven acute cellular rejection as an efficacy endpoint of randomized trials in liver transplantation: a systematic review and critical appraisal
- 29 January 2016
- journal article
- review article
- Published by Frontiers Media SA in Transplant International
- Vol. 29 (9) , 961-973
Abstract
Biopsy-proven acute cellular rejection (ACR) is the primary efficacy endpoint in most randomized trials evaluating immunosuppression in liver transplantation. However, ACR is not a major cause of graft loss, and a certain grade of immune activation may be even beneficial for long-term graft acceptance. Validated criteria to select candidates for liver biopsy are lacking, and routine clinical practice relies on liver tests, which are inaccurate markers of ACR. Indeed, both the agreement among clinicians to select candidates for liver biopsy and the correlation between the clinical suspicion of ACR and histological findings are poor. In randomized trials evaluating immunosuppression protocols, this concern grows exponentially due to the open-label and multicenter nature of most studies. Therefore, biopsy-proven ACR is a suboptimal efficacy endpoint given its limited impact on prognosis and the heterogeneous diagnosis, which may increase the risk of bias. Chronic rejection and/or graft loss would be more appropriate endpoints, but would certainly require larger studies with prolonged surveillances. An objective method to select candidates for liver biopsy is therefore urgently needed, and only severe episodes of histological ACR should be considered as potentially harmful. Emerging surrogate markers of ACR and antibody-mediated rejection require further investigation to determine their clinical role.Keywords
Funding Information
- European Association for the Study of the Liver (EASL)
- Fresenius Biotech
This publication has 108 references indexed in Scilit:
- Cytokine gene polymorphisms in acute cellular rejection following living donor liver transplantation: analysis of 155 donor-recipient pairsHepatology International, 2013
- Randomized, multicenter trial comparing tacrolimus plus mycophenolate mofetil to tacrolimus plus steroids in hepatitis C virus–positive recipients of living donor liver transplantationLiver Transplantation, 2013
- Completely steroid‐free immunosuppression in liver transplantation: a randomized studyClinical Transplantation, 2013
- A prospective, randomized trial of complete avoidance of steroids in liver transplantation with follow‐up of over 7 yearsHPB, 2013
- Everolimus With Reduced Tacrolimus Improves Renal Function in De Novo Liver Transplant Recipients: A Randomized Controlled TrialAmerican Journal of Transplantation, 2012
- A Randomized Multicenter Study Comparing a Tacrolimus-Based Protocol with and without Steroids in HCV-Positive Liver Allograft RecipientsJournal of Transplantation, 2012
- The Significance of Donor-Specific HLA Antibodies in Rejection and Ductopenia Development in ABO Compatible Liver TransplantationAmerican Journal of Transplantation, 2011
- Noninvasive diagnosis of acute cellular rejection in liver transplant recipients: A proteomic signature validated by enzyme-linked immunosorbent assayLiver Transplantation, 2011
- The immunological monitoring of kidney and liver transplants in adult and pediatric recipientsTransplant Immunology, 2009
- Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trialsBMJ, 2007